Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40

Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40

Background/Aims: Monoclonal antibodies (mAbs) are presently the most promising treatment against Ebola virus disease (EVD), and cocktail of two or more antibodies likely confers protection through complementary mechanisms. Zaire Ebolavirus (EBOV) glycoprotein (GP) and viral protein 40 (VP40) are tar...

Full description

Bibliographic Details
Main Authors: Dong-Shan Yu, Tian-Hao Weng, Ling Shen, Xiao-Xin Wu, Chen-Yu Hu, Frederick X.C. Wang, Zhi-Gang Wu, Hai-Bo Wu, Nan-Ping Wu, Lan-Juan Li, Hangping Yao
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2018-10-01
Series:Cellular Physiology and Biochemistry
Subjects:
Zaire Ebola virus
GP
VP40
TrVLP
Monoclonal antibody
Anti-viral effect
Online Access:https://www.karger.com/Article/FullText/494530

Internet

https://www.karger.com/Article/FullText/494530

Similar Items